Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 77, Issue 2, 2003, Pages 185-188

  Rimassa, Lorenza ^a   Carnaghi, Carlo ^a   Garassino, Isabella ^a   Salvini, Piermario ^a   Ginanni, Valeria ^a   Gullo, Giuseppe ^a   Morenghi, Emanuela ^a   Santoro, Armando ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Advanced breast cancer; Caelyx; Doxorubicin; Pegylated liposomal; Vinorelbine

Indexed keywords

ANTHRACYCLINE; ANTHRAQUINONE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; NAVELBINE; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; HUMANS; LIPOSOMES; MIDDLE AGED; NEOPLASM METASTASIS; REMISSION INDUCTION; TREATMENT OUTCOME; VINBLASTINE;

EID: 0037278328     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021300719965     Document Type: Article

References (16)

1. Hortobagyi GN: Anthracyclines in the treatment of cancer. Drugs 54 (suppl. 4): 1-7, 1997
2. Von Hoff DD, Layard MW, Basa P, Davis Jr HL, Von Hoff AL, Rozencweig M, Muggia FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710-717, 1979
3. Hellman K: Anthracycline cardiac toxicity by dexrazosane: breakthrough of a barrier-sharpens antitumor profile and therapeutic index (Editorial). J Clin Oncol 14: 332-333, 1996
4. Bonadonna G, Gianni L, Santoro A, Bonfante V, Bidoli P, Casali P, Demicheli R, Valagussa P: Drugs 10 years later: epirubicin. Ann Oncol 4: 359-369, 1993
5. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Coen R, Martin F, Huang A, Barenholz Y: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54: 987-992, 1994
6. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A: Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I study. J Clin Oncol 13: 1777-1785, 1995
7. Alberts DS, Garcia DJ: Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 54 (suppl. 4): 30-35, 1997
8. Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, Patek A, Martin FJ: The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 9: 711-716, 1998
9. 2. Ann Oncol 8: 1029-1033, 2000
10. Ranson MR, Cheeseman S, White S, Margison J: Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. Crit Rev Oncol Hematol 37: 115-120, 2001
11. Laufman LR, Spiridonidis CH, Jones JJ, Rhodes VA, Wallace K: Phase I trial of doxil plus vinorelbine in patients with advanced malignancies. Proc ASCO (Am Soc Clin Oncol) 17: 246 (abstract 944), 1998
12. Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP: Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol 10: 1113-1116, 1999
13. Norris B, Pritchard KI, James K, Myles J, Bennett K, Marlin S, Skillings J, Findlay B, Vandenberg T, Goss B, Latreille J, Rudinskas L, Lofters W, Trudeau M, Osoba D, Rodgers A: Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 18: 2385-2394, 2000
14. Simon R: Optimal two-stage designes for phase II clinical trials. Contr Clin Trials 10: 1-10, 1989
15. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in dose-finding and sequence-finding study. J Clin Oncol 13: 2688-2699, 1995
16. Slamon DL, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 344: 783-792, 2001